Actively Recruiting

Age: 50Years - 75Years
All Genders
NCT04743479

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

Led by Changhai Hospital · Updated on 2023-09-01

5000

Participants Needed

1

Research Sites

525 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \~6%\[1\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed. Identifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, "Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.

CONDITIONS

Official Title

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

Who Can Participate

Age: 50Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to provide informed consent and sign the consent form
  • Willing to complete a detailed questionnaire
  • Age between 50 and 75 years
  • Has new-onset diabetes diagnosed within the past 3 years, or
  • Has familial pancreatic cancer, or
  • Has inherited syndromes associated with pancreatic cancer (including hereditary pancreatitis, familial atypical multiple mole and melanoma syndrome, hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, hereditary breast and ovarian cancer syndromes), or
  • Has pancreatic cystic neoplasm (including IPMN, MCN), or
  • Has chronic pancreatitis
Not Eligible

You will not qualify if you...

  • Diagnosed with pancreatic cancer or other malignant tumors in the last 5 years
  • Has any medical condition that contraindicates high-resolution MRI or CT
  • Cannot be followed up or is currently participating in other clinical trials

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Changhai Hospital

Shanghai, China, 200433

Actively Recruiting

Loading map...

Research Team

B

Beilei Wang, M.D.

CONTACT

S

Shiwei Guo, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI) | DecenTrialz